Jerome Benedict Durso Purchases 20,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT) CEO Jerome Benedict Durso acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average price of $3.54 per share, with a total value of $70,800.00. Following the completion of the acquisition, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at $115,050. This trade represents a 160.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jerome Benedict Durso also recently made the following trade(s):

• On Monday, December 22nd, Jerome Benedict Durso bought 12,500 shares of Altimmune stock. The shares were bought at an average cost of $4.13 per share, for a total transaction of $51,625.00.

Altimmune Trading Down 0.5%

NASDAQ ALT opened at $3.86 on Wednesday. The business’s 50-day moving average price is $4.49 and its two-hundred day moving average price is $4.29. Altimmune, Inc. has a 12 month low of $2.90 and a 12 month high of $7.73. The firm has a market capitalization of $502.07 million, a PE ratio of -3.82 and a beta of 0.13. The company has a current ratio of 18.55, a quick ratio of 17.18 and a debt-to-equity ratio of 0.15.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on ALT shares. Citigroup restated a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday. B. Riley Financial decreased their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Barclays assumed coverage on shares of Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $16.60.

Hedge Funds Weigh In On Altimmune

Several institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. grew its position in shares of Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after buying an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares during the period. Concurrent Investment Advisors LLC lifted its position in shares of Altimmune by 10.4% during the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after acquiring an additional 2,500 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Altimmune by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after acquiring an additional 2,748 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in Altimmune by 4.0% during the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after acquiring an additional 3,047 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.